2-[[4-(1,3-benzodioxol-5-ylamino)-6-(2-methylbenzimidazol-1-yl)-1,3,5-triazin-2-yl]amino]ethanol;2-N-(1,3-benzodioxol-5-yl)-6-(2-methylbenzimidazol-1-yl)-1,3,5-triazine-2,4-diamine;6-(2-methylbenzimidazol-1-yl)-2-N-quinolin-3-yl-1,3,5-triazine-2,4-diamine;6-(2-methylimidazo[4,5-b]pyridin-1-yl)-2-N-[4-(trifluoromethyl)phenyl]-1,3,5-triazine-2,4-diamine
C75H63F3N30O5 — CID 158466051
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[[4-(1,3-benzodioxol-5-ylamino)-6-(2-methylbenzimidazol-1-yl)-1,3,5-triazin-2-yl]amino]ethanol;2-N-(1,3-benzodioxol-5-yl)-6-(2-methylbenzimidazol-1-yl)-1,3,5-triazine-2,4-diamine;6-(2-methylbenzimidazol-1-yl)-2-N-quinolin-3-yl-1,3,5-triazine-2,4-diamine;6-(2-methylimidazo[4,5-b]pyridin-1-yl)-2-N-[4-(trifluoromethyl)phenyl]-1,3,5-triazine-2,4-diamine
2-[[4-(1,3-benzodioxol-5-ylamino)-6-(2-methylbenzimidazol-1-yl)-1,3,5-triazin-2-yl]amino]ethanol;2-N-(1,3-benzodioxol-5-yl)-6-(2-methylbenzimidazol-1-yl)-1,3,5-triazine-2,4-diamine;6-(2-methylbenzimidazol-1-yl)-2-N-quinolin-3-yl-1,3,5-triazine-2,4-diamine;6-(2-methylimidazo[4,5-b]pyridin-1-yl)-2-N-[4-(trifluoromethyl)phenyl]-1,3,5-triazine-2,4-diamine (PubChem CID 158466051) has the molecular formula C75H63F3N30O5 and a molecular weight of 1521.53 g/mol. Its IUPAC name is 2-[[4-(1,3-benzodioxol-5-ylamino)-6-(2-methylbenzimidazol-1-yl)-1,3,5-triazin-2-yl]amino]ethanol;2-N-(1,3-benzodioxol-5-yl)-6-(2-methylbenzimidazol-1-yl)-1,3,5-triazine-2,4-diamine;6-(2-methylbenzimidazol-1-yl)-2-N-quinolin-3-yl-1,3,5-triazine-2,4-diamine;6-(2-methylimidazo[4,5-b]pyridin-1-yl)-2-N-[4-(trifluoromethyl)phenyl]-1,3,5-triazine-2,4-diamine.
Molecular Properties
| Compound Name | 2-[[4-(1,3-benzodioxol-5-ylamino)-6-(2-methylbenzimidazol-1-yl)-1,3,5-triazin-2-yl]amino]ethanol;2-N-(1,3-benzodioxol-5-yl)-6-(2-methylbenzimidazol-1-yl)-1,3,5-triazine-2,4-diamine;6-(2-methylbenzimidazol-1-yl)-2-N-quinolin-3-yl-1,3,5-triazine-2,4-diamine;6-(2-methylimidazo[4,5-b]pyridin-1-yl)-2-N-[4-(trifluoromethyl)phenyl]-1,3,5-triazine-2,4-diamine |
|---|---|
| PubChem CID | 158466051 |
| Molecular Formula | C75H63F3N30O5 |
| Molecular Weight | 1521.53 g/mol |
| Exact Mass | 1520.55 |
| IUPAC Name | 2-[[4-(1,3-benzodioxol-5-ylamino)-6-(2-methylbenzimidazol-1-yl)-1,3,5-triazin-2-yl]amino]ethanol;2-N-(1,3-benzodioxol-5-yl)-6-(2-methylbenzimidazol-1-yl)-1,3,5-triazine-2,4-diamine;6-(2-methylbenzimidazol-1-yl)-2-N-quinolin-3-yl-1,3,5-triazine-2,4-diamine;6-(2-methylimidazo[4,5-b]pyridin-1-yl)-2-N-[4-(trifluoromethyl)phenyl]-1,3,5-triazine-2,4-diamine |
| SMILES | Cc1nc2ccccc2n1-c1nc(N)nc(Nc2ccc3c(c2)OCO3)n1.Cc1nc2ccccc2n1-c1nc(N)nc(Nc2cnc3ccccc3c2)n1.Cc1nc2ccccc2n1-c1nc(NCCO)nc(Nc2ccc3c(c2)OCO3)n1.Cc1nc2ncccc2n1-c1nc(N)nc(Nc2ccc(C(F)(F)F)cc2)n1 |
| InChI | InChI=1S/C20H16N8.C20H19N7O3.C18H15N7O2.C17H13F3N8/c1-12-23-16-8-4-5-9-17(16)28(12)20-26-18(21)25-19(27-20)24-14-10-13-6-2-3-7-15(13)22-11-14;1-12-22-14-4-2-3-5-15(14)27(12)20-25-18(21-8-9-28)24-19(26-20)23-13-6-7-16-17(10-13)30-11-29-16;1-10-20-12-4-2-3-5-13(12)25(10)18-23-16(19)22-17(24-18)21-11-6-7-14-15(8-11)27-9-26-14;1-9-23-13-12(3-2-8-22-13)28(9)16-26-14(21)25-15(27-16)24-11-6-4-10(5-7-11)17(18,19)20/h2-11H,1H3,(H3,21,24,25,26,27);2-7,10,28H,8-9,11H2,1H3,(H2,21,23,24,25,26);2-8H,9H2,1H3,(H3,19,21,22,23,24);2-8H,1H3,(H3,21,24,25,26,27) |
| InChIKey | HFTLGJRXJLLTKE-UHFFFAOYSA-N |
| XLogP | 11.62 |
| TPSA | 447.10 Ų |
| H-Bond Donors | 9 |
| H-Bond Acceptors | 35 |
| Rotatable Bonds | 15 |
| Heavy Atoms | 113 |
| Complexity | — |
Lipinski Rule of Five
4 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 1521.53 |
| LogP ≤ 5 | 11.62 |
| H-Bond Donors ≤ 5 | 9 |
| H-Bond Acceptors ≤ 10 | 35 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 158466051 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.